Express your opinion about this website:
Traffic report about perjeta.com - here you can find answers to questions like these:
Our system has never spotted perjeta.com in Alexa ratings.
This fact suggests that domain has very low traffic.
The most recent time we have spotted perjeta.com on Quantcast list was on December 18, 2013 (3,792 days ago) and then the rank was 134,116. And this is a bit worse position than average position for perjeta.com in Quantcast.
Website is hosted on IP 72.34.128.214.
The host name of this IP address is perjeta-rwc.gene.com.
There are 1 websites hosted on exact the same IP and 87 websites that are hosted on similar IP address.
We have no data about websites that could be similar to perjeta.com.
We've checked perjeta.com recently and it was online. The load time was 0.2403 seconds slower than average. The size of document was 634 bytes longer than usually. The website contained 57 links less than the average.
We have no information if perjeta.com is optimised for mobile devices.
We did not encounter any safety threats while testing this website.
We did not find any data about perjeta.com being listed in the blacklists.
It seems that perjeta.com was never dropped before.
Click here to see the list of dropped domains
Our system found out that there could be 291 domains with the same beginning as perjeta.com
Our system found out that there could be 36 mistakes made in the typing process.
And here you'll find analysis of HTML code:
PROPERTY | VALUE |
---|---|
Keywords: | PERJETA, Herceptin, PERJETA and Herceptin, metastatic breast cancer treatment, pertuzumab, her2-positive metastatic breast cancer, Genentech, mbc, her2+, neoadjuvant |
WEB address: | http://perjeta.com/ |
Summary: | Learn about PERJETA®, a neoadjuvant and metastatic breast cancer treatment for patients with HER2-positive breast cancer. What does PERJETA treat? PERJETA® (pertuzumab) is approved for use in combination with Herceptin® (trastuzumab) and docetaxel in people who have HER2-positive breast cancer that has spread to different parts of the body (metastatic) and who have not received anti-HER2 therapy or chemotherapy for metastatic breast cancer. PERJETA® (pertuzumab) is approved for use prior to surgery in combination with Herceptin® (trastuzumab) and docetaxel in people with HER2-positive, locally advanced, inflammatory, or early stage (tumor is greater than 2 cm in diameter or node positive) breast cancer. PERJETA should be used as part of a complete treatment regimen for early stage breast cancer. This use of PERJETA is based on an improvement in the percentage of patients whose cancer shrinks or disappears after treatment. Currently, no data have shown whether or not treatment with PERJETA prior to surgery improves survival. • The safety of PERJETA in combination with doxorubicin-containing regimens has not been established • The safety of PERJETA administered for greater than 6 cycles for early-stage breast cancer has not been established. Important Safety Information • PERJETA may cause heart problems, including those without symptoms (such as reduced heart function) and those with symptoms (such as congestive heart failure) • Receiving PERJETA during pregnancy can result in the death of an unborn baby and birth defects — If you think you may be pregnant, you should contact your healthcare provider immediately — If you are exposed to PERJETA during pregnancy, or become pregnant while receiving PERJETA or within 7 months following the last dose of PERJETA in combination with Herceptin, you are encouraged to enroll in the MotHER Pregnancy Registry by contacting 1-800-690-6720 or visiting http://www.motherpregnancyregistry.com/ and report PERJETA exposure to Genentech at 1-888-835-2555 • PERJETA should not be used in patients who are allergic to pertuzumab or to any of the ingredients in PERJETA • Other possible serious side effects of PERJETA therapy include: — Infusion-related reactions — Severe allergic reactions (hypersensitivity reactions/anaphylaxis) • PERJETA has only been shown to work in people with HER2-positive breast cancer • The most common side effects of PERJETA when given with Herceptin and docetaxel for treatment of breast cancer that has spread to other parts of the body (metastatic) are: — Diarrhea — Hair loss — Low levels of white blood cells with or without a fever — Nausea — Feeling tired — Rash — Damage to the nerves (numbness, tingling, pain in hands/feet) • The most common side effects of PERJETA when given with Herceptin and docetaxel as part of an early breast cancer regimen before surgery are: — Hair loss — Diarrhea — Nausea — Low levels of white blood cells with or without a fever • The most common side effects of PERJETA when given with Herceptin and docetaxel following 3 cycles of epirubicin, cyclophosphamide, and fluorouracil as part of an early breast cancer regimen before surgery are: — Feeling tired — Hair loss — Diarrhea — Nausea — Vomiting — Low levels of white blood cells with or without a fever • The most common side effects of PERJETA when given with Herceptin, docetaxel, and carboplatin as part of an early breast cancer regimen before surgery are: — Feeling tired — Hair loss — Diarrhea — Nausea — Vomiting — Low levels of white blood cells with or without a fever — Low platelet count — Low levels of red blood cells You are encouraged to report side effects to Genentech and the FDA. You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555. Please see additional select Important Safety Information throughout, and the accompanying full Prescribing Information including most serious side effects. |
<title> | HER2+ Breast Cancer Treatment | PERJETA® (pertuzumab) |
Hosting information: | Click here for more hosting information |
Size of HTML code: | +634 bytes compared to average |
Total number of links: | -57 links compared to average |
Load time: | +0.24029435 seconds compared to average |
META TAG PROPERTY | VALUE |
Generator | Drupal 7 (http://drupal.org) |
No data about Alexa yet.
This table shows websites that use 72.34.128.214 (perjeta-rwc.gene.com) for hosting:
List of websites | IP address and hostname |
---|---|
72.34.128.214 perjeta-rwc.gene.com |
Note: The matching part of IP address is marked with this style.
Website: | perjeta.com |
---|---|
Most recent position: | 134,116 reached on December 18, 2013 (3,792 days ago) |
Times found in quant list: | 56 |
Average position: | 134,208 |
All time highest position: | 134,096 reached on December 17, 2013 (3,793 days ago) |
All time lowest position: | 134,300 reached on November 28, 2013 (3,812 days ago) |
There are 291 alternatives to perjeta.com
We believe that these mistakes can be made in the typing process of "perjeta.com":
No data about perjeta.com being in dropped domains database...